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Background: In KEYNOTE-010, pembro improved OS vs doce as 2L+ therapy for
advanced NSCLC with PD-L1 TPS 1% and 50%. KEYNOTE-010 did not enroll any pts
from mainland China, which has high NSCLC mortality. KEYNOTE-033 (NCT02864394)
evaluates pembro vs doce in pts with previously treated advanced NSCLC with PD-L1
TPS 1%, with most pts enrolled in mainland China.
Methods: Eligible pts (18 y) were randomized to pembro 2 mg/kg Q3W (35 cycles)
or doce 75 mg/m2 Q3W (per local standard of care), stratified by TPS (50% vs 1e
49%). Response was assessed Q9W per RECIST v1.1 by BICR. PD-L1 expression was
assessed centrally (PD-L1 IHC 22C3 pharmDx assay). OS and PFS (primary objectives)
were evaluated sequentially using stratified log-rank tests, first in pts with TPS 50%
and then in pts with TPS 1% (1-sided a¼0.025).
Results: 425 pts were enrolled. At data cutoff (Sep 9, 2019), median follow-up was
18.8 (range, 0.2-38.8) mo, and 291 (68%) pts had died. Pembro numerically improved
OS in all groups analyzed, but did not achieve predefined statistical significance in pts
with PD-L1 TPS 50% (Table); thus, sequential testing of OS and PFS ceased. HR for
OS in TPS 1% pts from mainland China (n¼311) was 0.68 (95% CI, 0.51e0.89). In all
treated pts, incidence of treatment-related AEs was lower with pembro vs doce (any
grade, 70% vs 88%; grade 3-5, 11% vs 47%).
Table: 1262P
Pembro DoceS816PD-L1 TPS 50% N¼114 N¼113
OS Median (95% CI), mo 12.3 (10.0-16.3) 10.9 (8.3-13.1)HR (95% CI) 0.83 (0.61-1.14)
P 0.1276PFS Median (95% CI), mo 4.0 (2.1-8.0) 2.5 (2.1-4.2)
HR (95% CI) 0.76 (0.54-1.07)ORR % (95% CI) 28.1 (20.1-37.3) 7.1 (3.1-13.5)
PD-L1 TPS 1% N¼213 N¼212
OS Median (95% CI), mo 12.9 (10.3-16.5) 10.6 (8.7-12.5)HR (95% CI) 0.75 (0.60-0.95)
PFS Median (95% CI), mo 3.3 (2.1-4.1) 3.0 (2.3-4.0)HR (95% CI) 0.84 (0.66-1.08)
ORR % (95% CI) 20.7 (15.4-26.7) 5.7 (3.0-9.7)Conclusions: While pembro did not meet statistical significance for OS in pts with PD-
L1 TPS 50%, HRs for OS and PFS numerically favored pembro and ORR was higher
with pembro in both the PD-L1 TPS 50% and 1% groups. Toxicity was consistent
with the established pembro safety profile. These data support the value of pembro
for previously treated advanced NSCLC in China.Clinical trial identification: NCT02864394.
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Background: Tislelizumab + chemotherapy has shown antitumor activity with a
favorable tolerability profile in patients (pts) with histologically confirmed nsq-NSCLC.
Methods: In this open-label phase 3 study (NCT03663205), Chinese pts were ran-
domized 2:1 to receive tislelizumab 200 mg + platinum (carboplatin AUC 5 or cisplatin
75 mg/m2) + pemetrexed 500 mg/m2, followed by maintenance tislelizumab +
pemetrexed (Arm A); pts in Arm B received platinum + pemetrexed and maintenance
pemetrexed. Patients with known EGFR mutations or ALK rearrangement were inel-
igible. Patients were stratified by disease stage (IIIB vs IV) and tumor cell PD-L1
expression (<1% vs 1-49% vs 50%) assessed using the Ventana PD-L1 (SP263) Assay.
Platinum was administered for 4-6 cycles at investigator’s discretion; crossover to
tislelizumab was allowed. Treatment beyond progression was allowed for tislelizumab.
The primary endpoint, progression-free survival per RECIST v1.1, was assessed by
Independent Review Committee (PFSIRC); key secondary endpoints included overall
survival (OS), objective response rate (ORRIRC), duration of response (DoRIRC), and
safety/tolerability.
Results: As of 23 Jan 2020, 334 pts with nsq-NSCLC (A, n¼223; B, n¼111) were
randomized; median study follow-up was 9.8 mo (95% CI: 9.23,10.38). PFSIRC was
significantly longer with tislelizumab combination therapy than chemotherapy alone
(P¼0.0044; HR¼0.645 [95% CI: 0.462, 0.902]; median PFSIRC, 9.7 mo vs 7.6 mo).
ORRIRC was 57% (95% CI: 50.6, 64.0) and 37% (95% CI: 28.0, 46.6) in Arms A and B,
respectively. Median DoR in Arm A was 8.5 mo (95% CI: 6.80, 10.58) and 6.0 mo (95%
CI: 4.99, NE) in Arm B. A total of 221 pts (99.5%) had a treatment-related AE (TRAE) in
Arm A; 185 pts (83%) had AEs related to tislelizumab. Of 140 pts (63%) with grade 3
TRAEs, 69 (31%) were considered related to tislelizumab by the investigator. In Arm B,
107 pts (97%) experienced 1 TRAE, of which 50 (46%) were grade 3. Across the
entire study, four pts (1%) had fatal pneumonitis; 3 of which were considered possibly
related to tislelizumab.
Conclusions: Tislelizumab plus chemotherapy was generally well tolerated and
demonstrated antitumor activity in pts with nsq-NSCLC.
Clinical trial identification: NCT03663205.
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